Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Stomach Neoplasms × sargramostim × Clear all

Phase

Status

Sponsor Class

OTHER 2 NIH 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 5 Glioblastoma 4 Breast Neoplasms 3 Pathologic Complete Response 2 Ovarian Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Glioma 1 Brain Neoplasms 1 Advanced Ovarian Cancer 1 Advanced Cancer 1

Interventions

Capecitabine 67 Oxaliplatin 63 pembrolizumab 61 Cisplatin 49 Fluorouracil 46 Paclitaxel 35 Nivolumab 33 Trastuzumab 29 Leucovorin 26 Docetaxel 22 Irinotecan 19 Ramucirumab 17 Bevacizumab 14 S 1 (combination) 13 Carboplatin 13 Gemcitabine 12 atezolizumab 11 apatinib 11 tislelizumab 10 fludarabine 9 Drug Therapy 9 Cyclophosphamide 9 trastuzumab deruxtecan 7 durvalumab 7 Ipilimumab 7 Injections 7 130-nm albumin-bound paclitaxel 7 titanium silicide 6 bemarituzumab 6 Folfox protocol 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05771584 2024-07-10

Conerstone3

Aston Sci. Inc.

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡